HomeFinTechChimeric Therapeutics: Raises $7.37m for licence agreements

Chimeric Therapeutics: Raises $7.37m for licence agreements

Date:

Paysafe Explores Potential Sale Amid Market Challenges

Could a Strategic Sale Turnaround Be on the Horizon...

Adviser Software and Intergen Data Reveal DeepSeek’s Key Risks

A Comprehensive Analysis of Risks Faced by DeepSeek in...

Gemini Explores Potential IPO Opportunities Amid Market Changes

A Deep Dive into Gemini's Strategies for an Initial...

Chimeric Therapeutics Raises $7.37m for licence agreements

  • Chimeric Therapeutics (CHM) successfully completes its institutional entitlement offer and raises $7.37 million
  • This institutional entitlement offer forms part of Chimeric’s $18.1 million entitlement offer with the money to be used to fund Chimeric’s licence and sponsored agreements
  • More than 43.33 million fully-paid ordinary shares were issued under the institutional component at 17 cents
  • Chimeric will now undertake the retail entitlement offer which is expected to raise up to $10.75 million
  • Shares in Chimeric were down 11.9 per cent at 17 cents
Exit mobile version